ALLO News and Press, Allogene Therapeutics Inc. From 02/28/23

Allogene Therapeutics, Inc. (ALLO) Q4 2022 Earnings Conference Call February 28, 2023, 17:00 ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Developm...

Allogene Therapeutics press release ( NASDAQ: ALLO ): Q4 GAAP EPS of -$0.66 beats by $0.04 . Revenue of $0.05M misses by $0.01M . The Company expects a decrease in cash, cash equivalents, and investments of approximately $250 million in 2023. Based on current expe...

Initiated Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) Presented Data Highlighting Industry-Leading Allogeneic CAR T Portfolio CD19 (ALLO-501/A): Six Month Durability and Progression Free Surv...

Allogene Therapeutics ( NASDAQ: ALLO ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.69 and the consensus Revenue Estimate is $0.06M (compared to $51M in year ago quarter). Over the last 3 months, ...

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for...

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’...

Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage bio...

Allogene Therapeutics ( NASDAQ: ALLO ) stock rose ~14% on Tuesday after JPMorgan Chase upgraded the shares to Overweight from Neutral with a price target of $11 from $20, based on fundamentals and near-term catalysts. The SA Quant Rating on ALLO is Hold , which is in...

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1 UNIVERSAL trial...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...